NasdaqCM:SLSBiotechs
Is SELLAS Life Sciences Group (SLS) Overvalued As Trial Milestones And Takeover Changes Stir Questions?
Trial Milestone and Executive Changes Put SELLAS Life Sciences Group Stock in Focus
SELLAS Life Sciences Group (SLS) drew attention after a report indicated its phase 3 trial for acute myeloid leukemia reached the 80th patient death, a key trigger for Galinpepimut S results.
The company has not commented on this reported milestone. Recent amendments to executive employment agreements that add takeover related benefits have prompted investors to reassess what might be next for the stock.
At a...